NCT03640247

Brief Summary

The purpose of this study is to evaluate the use of a non-narcotic, postoperative pain management regimen on patients undergoing thyroidectomy and parathyroidectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
126

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 24, 2018

Completed
28 days until next milestone

First Posted

Study publicly available on registry

August 21, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

November 15, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

December 26, 2019

Status Verified

December 1, 2019

Enrollment Period

1 year

First QC Date

July 24, 2018

Last Update Submit

December 23, 2019

Conditions

Keywords

ThyroidectomyParathryoidectomy

Outcome Measures

Primary Outcomes (1)

  • Overall mean pain as assessed by 10 point visual analogue scale from the 6 post operative day time points.

    10 point visual analogue scale- (0- no pain, 1-3 mild, 4-6 moderate pain, 7-10 severe pain).

    Overall mean pain score from 6 time points (Post operative days 0,1,2,3,4,5)

Secondary Outcomes (3)

  • Patient satisfaction with the pain medication regimen as assessed by 3-point likert scale from the 6 post operative day time points.

    Mean patient satisfaction score from 6 time points (Post operative days 0,1,2,3,4,5)

  • Total dose of oral narcotics converted into oral morphine equivalents (see below) that were taken by participants post-operatively

    Mean oral morphine equivalents from 6 time points (Post operative days 0,1,2,3,4,5)

  • Mean number of office calls/contacts from the 6 post operative day time points.

    Mean number of office calls/contacts from 6 time points (Post operative days 0,1,2,3,4,5)

Study Arms (2)

Narcotic group regimen

OTHER

* Tylenol tablet 1000 mg by mouth every 8 hours alternating with * Ibuprofen tablet 800 mg by mouth every 8 hours * Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg.

Drug: Narcotic group regimen

Non-narcotic group regimen

ACTIVE COMPARATOR

* Tylenol tablet 1000 mg by mouth every 8 hours alternating with * Ibuprofen tablet 800 mg by mouth every 8 hours

Drug: Non-narcotic group regimen

Interventions

Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen

Also known as: Ibuprofen 800mg every 8 hours, Acetaminophen 500Mg Tab x2 every 8 hours
Non-narcotic group regimen

Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.

Also known as: Ibuprofen 800mg every 8 hours, Oxycodone 5mg every 6 hours prn for pain., Hydrocodone 5 mg every 6 hours prn for pain, Tramadol 50 mg every 6 hours prn for pain, Acetaminophen 500Mg Tab x2 every 8 hours
Narcotic group regimen

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or greater
  • Undergoing total thyroidectomy, partial thyroidectomy or parathyroidectomy at MetroHealth Medical Center

You may not qualify if:

  • Patients taking narcotics prior to surgery
  • Patients who are unable or unwilling to follow study protocol requirements

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MetroHealth Medical Center

Cleveland, Ohio, 44109, United States

Location

Related Publications (6)

  • Fujii MH, Hodges AC, Russell RL, Roensch K, Beynnon B, Ahern TP, Holoch P, Moore JS, Ames SE, MacLean CD. Post-Discharge Opioid Prescribing and Use after Common Surgical Procedure. J Am Coll Surg. 2018 Jun;226(6):1004-1012. doi: 10.1016/j.jamcollsurg.2018.01.058. Epub 2018 Feb 28.

    PMID: 29499361BACKGROUND
  • Hill MV, Stucke RS, Billmeier SE, Kelly JL, Barth RJ Jr. Guideline for Discharge Opioid Prescriptions after Inpatient General Surgical Procedures. J Am Coll Surg. 2018 Jun;226(6):996-1003. doi: 10.1016/j.jamcollsurg.2017.10.012. Epub 2017 Nov 30.

    PMID: 29198638BACKGROUND
  • Long SM, Lumley CJ, Zeymo A, Davidson BJ. Prescription and Usage Pattern of Opioids after Thyroid and Parathyroid Surgery. Otolaryngol Head Neck Surg. 2019 Mar;160(3):388-393. doi: 10.1177/0194599818779776. Epub 2018 May 29.

    PMID: 29807482BACKGROUND
  • Lou I, Chennell TB, Schaefer SC, Chen H, Sippel RS, Balentine C, Schneider DF, Moalem J. Optimizing Outpatient Pain Management After Thyroid and Parathyroid Surgery: A Two-Institution Experience. Ann Surg Oncol. 2017 Jul;24(7):1951-1957. doi: 10.1245/s10434-017-5781-y. Epub 2017 Feb 3.

    PMID: 28160140BACKGROUND
  • Tan WH, Yu J, Feaman S, McAllister JM, Kahan LG, Quasebarth MA, Blatnik JA, Eagon JC, Awad MM, Brunt LM. Opioid Medication Use in the Surgical Patient: An Assessment of Prescribing Patterns and Use. J Am Coll Surg. 2018 Aug;227(2):203-211. doi: 10.1016/j.jamcollsurg.2018.04.032. Epub 2018 May 7.

    PMID: 29746919BACKGROUND
  • Brady JT, Dreimiller A, Miller-Spalding S, Gesang T, Sehgal AR, McHenry CR. Are narcotic pain medications necessary after discharge following thyroidectomy and parathyroidectomy? Surgery. 2021 Jan;169(1):202-208. doi: 10.1016/j.surg.2020.03.027. Epub 2020 May 14.

MeSH Terms

Conditions

Thyroid DiseasesParathyroid Diseases

Interventions

IbuprofenAcetaminophenOxycodoneHydrocodoneTramadol

Condition Hierarchy (Ancestors)

Endocrine System Diseases

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAcetanilidesAnilidesAmidesAniline CompoundsAminesCodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsCyclohexanolsHexanolsFatty AlcoholsAlcoholsDimethylaminesMethylaminesLipids

Study Officials

  • Christopher R McHenry, MD

    MetroHealth Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Masking Details
All party or parties involved have knowledge of the interventions assigned to individual participants
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Director, Division of General Surgery

Study Record Dates

First Submitted

July 24, 2018

First Posted

August 21, 2018

Study Start

November 15, 2018

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

December 26, 2019

Record last verified: 2019-12

Locations